| 000 | 01570 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250514015649.0 | ||
| 264 | 0 | _c20020517 | |
| 008 | 200205s 0 0 eng d | ||
| 022 | _a1471-4892 | ||
| 024 | 7 |
_a10.1016/s1471-4892(01)00028-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSzapary, P O | |
| 245 | 0 | 0 |
_aPharmacological management of high triglycerides and low high-density lipoprotein cholesterol. _h[electronic resource] |
| 260 |
_bCurrent opinion in pharmacology _cApr 2001 |
||
| 300 |
_a113-20 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAcids, Acyclic _xtherapeutic use |
| 650 | 0 | 4 |
_aCholesterol, HDL _xmetabolism |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCoronary Disease _xetiology |
| 650 | 0 | 4 | _aEpidemiologic Studies |
| 650 | 0 | 4 |
_aFatty Acids, Omega-3 _xtherapeutic use |
| 650 | 0 | 4 | _aHealth Behavior |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydroxymethylglutaryl-CoA Reductase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aHypertriglyceridemia _xcomplications |
| 650 | 0 | 4 |
_aHypolipidemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aHypolipoproteinemias _xcomplications |
| 650 | 0 | 4 |
_aNiacin _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptors, Cytoplasmic and Nuclear _xagonists |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTranscription Factors _xagonists |
| 650 | 0 | 4 |
_aTriglycerides _xmetabolism |
| 700 | 1 | _aRader, D J | |
| 773 | 0 |
_tCurrent opinion in pharmacology _gvol. 1 _gno. 2 _gp. 113-20 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s1471-4892(01)00028-5 _zAvailable from publisher's website |
| 999 |
_c11628697 _d11628697 |
||